A Dual‐Adjuvanted Parenteral‐Intranasal Subunit Nanovaccine generates Robust Systemic and Mucosal Immunity Against SARS‐CoV‐2 in Mice
Abstract: Existing parenteral SARS‐CoV‐2 vaccines produce only limited mucosal responses, essential for reducing transmission and achieving sterilizing immunity. Appropriately designed mucosal boosters can overcome the shortcomings of parenteral vaccines and enhance pre‐existing systemic immunity. Here, a new protein subunit nanovaccine is developed by utilizing dual‐adjuvanted (RIG‐I: PUUC RNA and TLR‐9: CpG DNA) polysaccharide‐amino acid‐lipid nanoparticles (PAL‐NPs) along with SARS‐CoV‐2 S1 trimer protein, that can be delivered both intramuscularly (IM) and intranasally (IN) to generate balanced mucosal‐systemic SARS‐CoV‐2 immunity. Mice receiving IM‐Prime PUUC+CpG PAL subunit nanovaccine, followed by an IN‐Boost, developed high levels of IgA, IgG, and cellular immunity in the lungs and showed robust systemic humoral immunity. Interestingly, as a purely intranasal subunit vaccine (IN‐Prime/IN‐Boost), PUUC+CpG PAL‐NPs induced stronger lung‐specific T cell immunity than IM‐Prime/IN‐Boost, and a comparable IgA and neutralizing antibodies, although with a lower systemic antibody response, indicating that a fully mucosal delivery route for SARS‐CoV‐2 vaccination may also be feasible. The data suggest that PUUC+CpG PAL subunit nanovaccine is a promising candidate for generating SARS‐CoV‐2 specific mucosal immunity.
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
A Dual‐Adjuvanted Parenteral‐Intranasal Subunit Nanovaccine generates Robust Systemic and Mucosal Immunity Against SARS‐CoV‐2 in Mice ; day:01 ; month:10 ; year:2024 ; extent:17
Advanced science ; (01.10.2024) (gesamt 17)
- Creator
-
Pandey, Bhawana
Wang, Zhengying
Jimenez, Angela
Bhatia, Eshant
Jain, Ritika
Beach, Alexander
Maniar, Drishti
Hosten, Justin
O'Farrell, Laura
Vantucci, Casey
Hur, David
Noel, Richard
Rinqguist, Rachel
Smith, Clinton
Ochoa, Miguel A.
Roy, Krishnendu
- DOI
-
10.1002/advs.202402792
- URN
-
urn:nbn:de:101:1-2410021412001.228526581182
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Pandey, Bhawana
- Wang, Zhengying
- Jimenez, Angela
- Bhatia, Eshant
- Jain, Ritika
- Beach, Alexander
- Maniar, Drishti
- Hosten, Justin
- O'Farrell, Laura
- Vantucci, Casey
- Hur, David
- Noel, Richard
- Rinqguist, Rachel
- Smith, Clinton
- Ochoa, Miguel A.
- Roy, Krishnendu
Other Objects (12)
Immunogenicity of intraperitoneal and intranasal liposome adjuvanted VLP vaccines against SARS-CoV-2 infection
Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects
Intranasal administration of unadjuvanted SARS‐CoV‐2 spike antigen boosts antigen‐specific immune responses induced by parenteral protein subunit vaccine prime in mice and hamsters
Adjuvanted infuenza vaccine dynamics
Adjuvanted influenza vaccine dynamics
Intranasal immunization with a proteosome-adjuvanted SARS-CoV-2 spike protein-based vaccine is immunogenic and efficacious in mice and hamsters
Intranasal delivery of a subunit protein vaccine provides protective immunity against JN.1 and XBB-lineage variants
Parenteral nutrition
Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19
A CpG-adjuvanted intranasal enterovirus 71 vaccine elicits mucosal and systemic immune responses and protects human SCARB2-transgenic mice against lethal challenge
Parenteral übertragbare Infektionen
National Development Generates National Identities
Immunogenicity of intraperitoneal and intranasal liposome adjuvanted VLP vaccines against SARS-CoV-2 infection
Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects
Intranasal administration of unadjuvanted SARS‐CoV‐2 spike antigen boosts antigen‐specific immune responses induced by parenteral protein subunit vaccine prime in mice and hamsters
Adjuvanted infuenza vaccine dynamics
Adjuvanted influenza vaccine dynamics
Intranasal immunization with a proteosome-adjuvanted SARS-CoV-2 spike protein-based vaccine is immunogenic and efficacious in mice and hamsters
Intranasal delivery of a subunit protein vaccine provides protective immunity against JN.1 and XBB-lineage variants
Parenteral nutrition
Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19
A CpG-adjuvanted intranasal enterovirus 71 vaccine elicits mucosal and systemic immune responses and protects human SCARB2-transgenic mice against lethal challenge
Parenteral übertragbare Infektionen
National Development Generates National Identities
Immunogenicity of intraperitoneal and intranasal liposome adjuvanted VLP vaccines against SARS-CoV-2 infection
Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects
Intranasal administration of unadjuvanted SARS‐CoV‐2 spike antigen boosts antigen‐specific immune responses induced by parenteral protein subunit vaccine prime in mice and hamsters
Adjuvanted infuenza vaccine dynamics
Adjuvanted influenza vaccine dynamics
Intranasal immunization with a proteosome-adjuvanted SARS-CoV-2 spike protein-based vaccine is immunogenic and efficacious in mice and hamsters
Intranasal delivery of a subunit protein vaccine provides protective immunity against JN.1 and XBB-lineage variants
Parenteral nutrition
Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19
A CpG-adjuvanted intranasal enterovirus 71 vaccine elicits mucosal and systemic immune responses and protects human SCARB2-transgenic mice against lethal challenge
Parenteral übertragbare Infektionen